Thomas P. Laughren

Psychiatry

4709 Kemper St
Rockville, MD 20853

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Commentary on "Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia (CIAS) and Other Neuropsychiatric Conditions: Insights from Two Decades of Clinical Trials".

Commentary on "Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia (CIAS) and Other Neuropsychiatric Conditions: Insights from Two Decades of Clinical Trials".

Journal: Schizophrenia bulletin

Published: August 15, 2024

A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.

A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.

Journal: Molecular psychiatry

Published: August 29, 2021

Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment.

Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment.

Journal: Journal of clinical pharmacology

Published: April 27, 2021

A Growing Crisis in Schizophrenia Drug Development: Failing Signal Detection at North American and Other Clinical Trial Sites.

A Growing Crisis in Schizophrenia Drug Development: Failing Signal Detection at North American and Other Clinical Trial Sites.

Journal: The Journal of clinical psychiatry

Published: March 07, 2020

Mitigating the Effects of Nonadherence in Clinical Trials.

Mitigating the Effects of Nonadherence in Clinical Trials.

Journal: Journal of clinical pharmacology

Published: November 02, 2015

Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia.

Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia.

Journal: Innovations in clinical neuroscience

Published: May 16, 2015

Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms.

Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms.

Journal: Schizophrenia research

Published: July 23, 2014

Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.

Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.

Journal: Journal of affective disorders

Published: June 20, 2014

Female reproductive life cycle and hormones: methodology to improve clinical trials.

Female reproductive life cycle and hormones: methodology to improve clinical trials.

Journal: The Journal of clinical psychiatry

Published: August 15, 2013

Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration.

Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration.

Journal: The Journal of clinical psychiatry

Published: August 07, 2013

Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.

Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.

Journal: Innovations in clinical neuroscience

Published: July 25, 2013

Commentary on "Regulatory issues in drug development programs targeting cognitive impairment in schizophrenia".

Commentary on "Regulatory issues in drug development programs targeting cognitive impairment in schizophrenia".

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: May 14, 2013

Showing 1-12 of 17

Last Updated: 09/26/2026